The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Grade 3 breast tumors generally have worse prognoses, but SEER data showed that Oncotype DX can identify a large proportion of patients who do well without chemo.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
Lebanon-based Cryogene and its subsidiary will distribute the gene expression-based test for breast cancer recurrence in the region.
Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The molecular analysis firm saw instrument sales rise 62 percent, and announced plans for a new digital spatial profiling instrument.
OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.